Propel Bio Management LLC Buys 212,457 Shares of Delcath Systems, Inc. $DCTH

Propel Bio Management LLC grew its stake in shares of Delcath Systems, Inc. (NASDAQ:DCTH) by 94.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 438,509 shares of the company’s stock after buying an additional 212,457 shares during the quarter. Delcath Systems comprises 4.7% of Propel Bio Management LLC’s holdings, making the stock its 8th biggest position. Propel Bio Management LLC owned about 1.24% of Delcath Systems worth $4,714,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently made changes to their positions in the company. Marshall Wace LLP acquired a new position in shares of Delcath Systems during the second quarter valued at approximately $6,572,000. Rosalind Advisors Inc. lifted its position in Delcath Systems by 13.8% in the second quarter. Rosalind Advisors Inc. now owns 3,300,389 shares of the company’s stock worth $44,885,000 after purchasing an additional 400,000 shares during the period. Geode Capital Management LLC boosted its stake in Delcath Systems by 128.1% during the 2nd quarter. Geode Capital Management LLC now owns 703,171 shares of the company’s stock valued at $9,565,000 after purchasing an additional 394,902 shares in the last quarter. Jump Financial LLC boosted its stake in Delcath Systems by 604.9% during the 2nd quarter. Jump Financial LLC now owns 197,466 shares of the company’s stock valued at $2,686,000 after purchasing an additional 169,453 shares in the last quarter. Finally, Simplify Asset Management Inc. increased its position in shares of Delcath Systems by 144.9% during the 3rd quarter. Simplify Asset Management Inc. now owns 261,126 shares of the company’s stock valued at $2,807,000 after purchasing an additional 154,497 shares during the period. 61.12% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Delcath Systems

Here are the key news stories impacting Delcath Systems this week:

• Positive Sentiment: Publication of CHOPIN Phase 2 trial in The Lancet Oncology — The full, investigator‑initiated CHOPIN randomized Phase 2 results led by Prof. Ellen Kapiteijn were published, increasing clinical visibility and credibility for Delcath’s liver‑directed chemotherapy platform; this type of high‑profile peer‑reviewed publication can support investor confidence and future regulatory/commercial discussions. Article Title Business Wire Release
• Neutral Sentiment: HC Wainwright maintains a Buy rating and a $30 price target — the firm continues to show long‑term conviction even as it revises near‑term numbers, which may temper negative reactions relative to a full downgrade.
• Neutral Sentiment: Long‑range forecasts mixed — HC Wainwright published multi‑year model estimates (including a new FY2030 EPS projection), showing a path to profitability further out; these farther‑out estimates are informative but less likely to move the stock as much as near‑term revisions.
• Neutral Sentiment: Short interest report shows no meaningful data change — the reported short interest figures appear to be zero/erroneous and do not indicate increased short pressure at this time.
• Negative Sentiment: Multiple downward EPS revisions from HC Wainwright — the analyst cut Q1–Q4 2026 and FY2026 estimates significantly (examples: Q1 from $0.13 to ($0.01), Q2 from $0.08 to ($0.15), Q3 from $0.10 to ($0.42), and FY2026 from $0.58 to ($0.86)), and lowered FY2027‑FY2029/FY2028/FY2029 forecasts as well. Those near‑term cuts increase uncertainty about upcoming quarters and could limit upside despite the trial publication.

Delcath Systems Stock Up 7.3%

Shares of Delcath Systems stock opened at $9.23 on Thursday. The stock’s fifty day moving average is $9.91 and its 200-day moving average is $10.16. The firm has a market capitalization of $320.74 million, a PE ratio of 131.86 and a beta of 0.38. Delcath Systems, Inc. has a 12-month low of $8.12 and a 12-month high of $18.23.

Delcath Systems (NASDAQ:DCTH) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01. The business had revenue of $20.73 million during the quarter, compared to analyst estimates of $20.35 million. Delcath Systems had a return on equity of 2.63% and a net margin of 3.17%. Analysts expect that Delcath Systems, Inc. will post -0.79 EPS for the current year.

Delcath Systems declared that its board has approved a share repurchase program on Thursday, November 20th that permits the company to repurchase $25.00 million in shares. This repurchase authorization permits the company to reacquire up to 8.6% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company’s board believes its stock is undervalued.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. Stephens cut their price objective on Delcath Systems from $25.00 to $18.00 and set an “overweight” rating for the company in a report on Wednesday, November 5th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of Delcath Systems in a report on Friday, January 9th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Delcath Systems in a research report on Monday, December 29th. Wall Street Zen lowered shares of Delcath Systems from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Finally, Evercore set a $27.00 price objective on shares of Delcath Systems in a research note on Thursday, February 26th. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Delcath Systems has an average rating of “Moderate Buy” and a consensus target price of $22.50.

Delcath Systems Profile

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.